{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-006481","form_type":"8-K","ticker":"MTNB","cik":"0001582554","company_name":"Matinas BioPharma Holdings, Inc.","filed_at":"2025-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.072867+00:00","generated_at":"2026-05-26T22:17:18.073174+00:00","sec_items":["1.01","3.02","3.03","5.02","5.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Matinas raises $3.3M via Series C preferred and warrants; appoints Dr. Robin Smith to board","bullets":["Initial closing of $1.65M for 1,650 Series C shares; second $1.65M closing subject to shareholder approval by April 10, 2025.","Series C convertible at $0.586/share; warrants exercisable at $0.6446 for 5 years post-shareholder approval.","Proceeds to reduce operating expenses and explore strategic alternatives for MAT2203 and other options.","Dr. Robin L. Smith appointed to board; Herbert J. Conrad resigns as founding Chairman and retires.","Company required to file resale registration statement by 15th day after 2024 10-K filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-006481","json":"https://secwatch.observer/filing/0001493152-25-006481.json","markdown":"https://secwatch.observer/filing/0001493152-25-006481.md","text":"https://secwatch.observer/filing/0001493152-25-006481.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582554/000149315225006481/0001493152-25-006481-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582554/000149315225006481/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T22:17:18.073174+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d2098f9c32","claim":"Robin Smith was appointed as Director at Matinas BioPharma Holdings, Inc..","evidence_excerpt":"the Board, on the recommendation of its Nominating and Corporate Governance Committee, appointed Robin Smith director of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1582554/000149315225006481/0001493152-25-006481-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}